December 18, 2017 / 6:10 AM / a month ago

BRIEF-Regeneron And Isa Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration

Regeneron Pharmaceuticals Inc:

* REGENERON AND ISA PHARMACEUTICALS ANNOUNCE STRATEGIC IMMUNO-ONCOLOGY COLLABORATION

* ‍REGENERON AND ISA WILL SHARE CLINICAL TRIAL COSTS AND EXCHANGE PRODUCT SUPPLY​

* REGENERON PHARMACEUTICALS- CO AND ISA WILL JOINTLY FUND AND CONDUCT CLINICAL TRIALS OF COMBINATION TREATMENT IN CERVICAL CANCER AND HEAD-AND-NECK CANCER

* SAYS FURTHER FINANCIAL DETAILS WERE NOT DISCLOSED

* REGENERON PHARMACEUTICALS -‍IN ADDITION, CO WILL PROVIDE UPFRONT PAYMENT, EQUITY INVESTMENT IN EXCHANGE FOR OPTION TO EXCLUSIVE GLOBAL LICENSE FOR ISA101​

* SAYS ANNOUNCED A CLINICAL COLLABORATION TO ADVANCE ISA101, AN IMMUNOTHERAPY TARGETING HPV16-INDUCED CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below